Phase 2 N=18 Use of F-652 in Patients With Alcoholic Hepatitis
Alcoholic Hepatitis
Primary: The Number of Subjects With Unexpected Serious Adverse Events. — 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=104 Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis
Acute Alcoholic Hepatitis
Primary: 180 Days Mortality — 17; 22; 0 Participants — p=.30
Phase 2 N=4 A Safety and Efficacy Study of Mycophenolate Mofetil and Rilonacept in Patients With Alcoholic Hepatitis
Alcoholic Hepatitis
Primary: Survival at Day 29 of the Assigned Treatment — 2; 0; 1; 1 Participants
Phase 2 N=147 Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis
Alcoholic Hepatitis
Primary: Survival at 90 Days — 90; 70 percentage of participants
Phase 2 N=55 IL-1 Signal Inhibition in Alcoholic Hepatitis
Alcoholic Hepatitis
Primary: Number of Patients Presenting Histological Improvement of Alcoholic Hepatitis on Liver Biopsy After 28 Days of Treatment Compared to Baseline. — 14; 10 Participants…
Phase 4 N=130 Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease
Alcoholic Liver Disease
Primary: Liver Enzymes(ALT) — 66; 48 IU/L
Phase 3 N=91 Effects of SAMe in Patients With Alcoholic Liver Disease
Liver Disease, Alcoholic
Primary: Changes in Serum AST Levels — -13.5; -56 Units per liter (U/L)
Phase 2 N=57 Safety and Efficacy of IMM 124-E for Patients With Severe Alcoholic Hepatitis
Hepatitis, Alcoholic
Primary: Gastrointestinal Safety Endpoints — 15; 27; 7; 14 Incidents
Phase 2 N=104 Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH)
Alcoholic Hepatitis (AH)
Primary: Percentage of Participants With Treatment-Emergent (TE) Adverse Events (AE), Serious AEs (SAE), AEs Leading to Premature Study Drug Discontinuation, and Grade 3 or 4…
Phase 2 N=19 A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis
Alcoholic Hepatitis
Primary: Lille Model for Alcoholic Hepatitis Score — 0.020; 0.050; 0.155; 0.195 score on a scale
N/A N=37 Biobehavioral Pathways Underlying Alcohol Use and Health
Alcohol Use Disorder · Liver Diseases
Primary: Percentage of Screen Eligible Who Enroll — 28; 5 Participants
Phase 3 N=203 Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure
Acute Alcoholic Hepatitis
Primary: Overall Survival — 57; 66 Participants — p=0.904
N/A N=33 Alcohol Biosensor Monitoring for Alcoholic Liver Disease
Alcohol Use, Unspecified
Primary: Alcohol Use — 7.4; 5.3; 4.4 drinks per episode
N/A N=1,133 Alcoholic Hepatitis Network Observational Study
Alcoholic Hepatitis
Primary: Number of Subjects With Clinical Data Collected — 717; 257; 159 Participants
N/A N=2,600 Chinese CLIF-C Acute-on-Chronic Liver Disease and Liver Failure Study
Liver Failure, Acute on Chronic
Primary: 28-day Mortality,28-day Liver-transplantation Free Mortality& 28-day Liver Transplantation Rate — 74; 124; 74 Participants
Phase 4 N=16 Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics
Genotype 1 Hepatitis C Virus
Primary: The Number of Subjects Who Achieve Negative RNA in Alcoholics — 14 Participants
Phase 3 N=76 13C-Methacetin Breath Test for the Prediction of Outcome in in ALI or ALF
Acute Liver Failure
Primary: Peak Percent Dose Recovery (PDR) Value — 10.2; 1.9 percentage per hour
Phase 3 N=410 Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites
Decompensated Cirrhosis and Ascites
Primary: Time to Liver Transplantation or Death Through 1 Year After Randomization: Percentage of Participants With an Event — 33.5; 38.6 percentage of participants — p=0.17
Phase 2 N=80 Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver · Nonalcoholic Steatohepatitis
Primary: Absolute Change in Intrahepatic Lipid Content, by 1H-MRS — -6.6; 3.6 Mean absolute percentage change
Phase 2 N=32 Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism
Aldehyde Dehydrogenase-2 (ALDH2) Deficiency
Primary: Number of Participants With Adverse Events (AEs), Serious AEs, and AEs Leading to Study Discontinuation — 13; 6; 8; 21 Participants
Phase 2 N=20 Vitamin C Infusion for TReatment in Sepsis and Alcoholic Hepatitis
Alcoholic Hepatitis · Sepsis
Primary: Change in Model for End Stage Liver Disease (MELD) Score — -0.13; -2.9; -2.3; -2.4 score on a scale
N/A N=30 Effect of Heavy Alcohol Consumption on Farnesoid X Receptor (FXR) Signaling
Alcohol Consumption
Primary: Change in Bile Salt Metabolism (C4 )Levels to Determine Effect of FXR
Phase 2 N=18 Treating Nonalcoholic Steatohepatitis With Pioglitazone
Hepatitis
Primary: Number of Patients With Improvement in Liver Histology — 12 participants
N/A N=34 Transient Elastography in Autoimmune Hepatitis
Liver Cirrhosis
Primary: Sensitivity and Specifity of Transient Elastography in Detection of Liver Cirrhosis — 0.83; 1.00; 1.00; 0.97 Probability
N/A N=139 Study of the Effects of Motivational Enhancement Therapy on Alcohol Use in Chronic Hepatitis C Patients
Alcohol Dependence · Chronic Hepatitis C
Primary: The Number of Alcohol Drinks Per Week (as Measured by the Time Line Follow Back Procedure) at the 6 Month Follow-up. — 14.88; 21.41 Standard Alcohol drinks
Phase 4 N=180 Baclofen to Reduce Alcohol Use in Veterans With HCV
Hepatitis C · Alcohol Use Disorders
Primary: Number of Drinking Days in the Past Two Weeks — 8.6; 8.9; 6.8; 7.1 Number of Drinking Days/2 weeks — p=<0.01
Phase 2 N=47 Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury
Acute Liver Failure · Acute Liver Injury
Primary: Number of Participants That do Not Tolerate the Administered Dose and Had Grade 3 or 4 Treatment Emergent Adverse Events as a Measure of Safety and Tolerability — 0; 0…
N/A N=14 Team Science (The Liver Health Study)
Steatotic Liver Disease of Mixed Origin (MetALD)
Primary: Proportion Screened With Alcohol Intake and Weight-related Risks for Metabolism and Alcohol-associated Liver Disease — 26 Participants
Phase 3 N=95 Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?
Adrenal Insufficiency · Cirrhosis · Spur Cell Anemia
Primary: Number of Participants With Cholesterol Esterification Deficiency — 10; 11 Participants
Phase 2 N=30 N-acetylcysteine Treatment of Alcohol Use Disorder In Veterans With TBI
Traumatic Brain Injury (TBI) · Hazardous and Harmful Alcohol Use
Primary: Change in Percent of Heavy Drinking Days Per Week as Assessed by the Timeline Followback (TFLB) — 26.2; 26.5 change in percent heavy drinking days/wk